3SBio Inc. has released its 2025 interim results, reporting steady revenue of 4.4 billion RMB, maintaining stable levels compared to the previous year. The net profit attributable to owners of the parent increased to 1.4 billion RMB, marking a year-over-year growth of 24.6%. EBITDA also saw an increase, reaching 1.8 billion RMB, which is an 11.6% rise from the first half of 2024. The company has optimized its financial structure, with interest-bearing liabilities and bonds decreasing from 3.5 billion RMB at the end of 2024 to 1.9 billion RMB. This resulted in a reduction of finance costs by 49%. Additionally, the gearing ratio improved, decreasing from 19.7% at the end of 2024 to 9.9%. 3SBio's core products have shown mixed performance. TPIAO, a recombinant human thrombopoietin injection, generated revenue of 2.4 billion RMB, reflecting a slight year-over-year decline of 4.2%. In contrast, Mandi products, including minoxidil tincture and foam, reported a revenue increase to 680 million RMB, up 24.0% from the previous year. Subsidiary Sunshine Guojian's products also saw a revenue increase to 642 million RMB, a 7.6% rise year-over-year. 3SBio is actively investing in research and development, with over 30 R&D pipeline candidates targeting innovative drug targets. The company aims to enhance its global supply chain and commercialization capabilities, with 10+ new drugs ready for launch. The international expansion continues with products like EPIAO, Yisaipu, SEPO, and TPIAO, expanding their presence in global markets.